13-hydroxy-9,11-octadecadienoic acid

Subscribe to Selected New Research on 13-hydroxy-9,11-octadecadienoic acid

56 relevant articles (1 outcomes, 6 trials/studies) found for this Bio-Agent

Description: chemorepellant factor which maintains blood vessel wall thromboresistance; RN given refers to unspecified stereoisomer

Also Known As:

13-HODD; 13-HODE; 13-LOX; 13-hydroxy-9,11-octadecadienoic acid, (E,E)-isomer; 13-hydroxy-9,11-octadecadienoic acid, (E,Z)-isomer; 13-hydroxy-9,11-octadecadienoic acid, (R)-(E,Z)-isomer; 13-hydroxy-9,11-octadecadienoic acid, (S)-(E,Z)-isomer; 13-hydroxy-9,11-octadecadienoic acid, (Z,E)-isomer; 13-hydroxyoctadecadienoic acid; 9,11-octadecadienoic acid, 13-hydroxy-

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13330

Fatty Acids: 4673

Unsaturated Fatty Acids: 2227

Essential Fatty Acids: 461

Linoleic Acids: 42

13-hydroxy-9,11-octadecadienoic acid: 56

Omega-6 Fatty Acids: 174

Linoleic Acids: 42

13-hydroxy-9,11-octadecadienoic acid: 56

Experts

1.	Krause, Jean A: 1 article (06/2004)
2.	Sauer, Leonard A: 1 article (06/2004)
3.	Dauchy, Robert T: 1 article (06/2004)
4.	Blask, David E: 1 article (06/2004)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2006 - "Finally, both 13-HODE and 13-OXO were shown to be inducers of GST activity in HT-29 and HCT-116 colon tumor cells" 06/01/2003 - "Tumor LA uptake and its metabolism to the mitogen 13-hydroxyoctadecadienoic acid (13-HODE) were also substantially higher under constant light conditions" 09/15/2000 - "A specific decrease in LA uptake and its conversion to the mitogen 13-HODE causes the tumor growth inhibition." 09/15/1999 - "The role of 13-HODE in LA-dependent growth of solid tumors is not known" 10/29/1997 - "Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines." Order ALL the reference details at left...
2.	Adhesions 09/29/1989 - "In this study we have bound a purified 13-HODE to a thrombogenic surface and its effect on platelet adhesion was studied and compared to the effects of an analogous hydroxy fatty acid, 15-hydroxyeicosatetraenoic acid (15-HETE)" 09/01/1992 - "Endothelial cells generate several thromborepellant factors including 13-hydroxyoctadecadienoic acid (13-HODE), an inhibitor of platelet adhesion to subendothelium" 09/01/1990 - "Alternatively, enhancing 13-HODE synthesis in either TCs or ECs (by elevating the resting levels of intracellular cAMP) was associated with decreased TC adhesion to ECs and ECM" 02/19/1990 - "Platelet/endothelial cell adhesion was inversely proportional to 13-HODE synthesis" 02/19/1990 - "We performed experiments, therefore, to determine the relationship between basal levels of cAMP, 13-HODE synthesis, and platelet/endothelial cell adhesion" Order ALL the reference details at left...
3.	Hepatocellular Carcinoma (Hepatoma) 09/15/1999 - "These results provide strong evidence that 13-HODE is the mitogenic signal responsible for LA-dependent growth in hepatoma 7288CTC in vivo." 09/15/1999 - "Hepatoma 7288CTC removed LA from the arterial blood and released 13-HODE [and a small amount of 13-ketooctadecadienoic acid (KODE)] into the venous blood both in vivo and during perfusion" 10/01/1997 - "Production of 13-HODE by the hepatomas in groups I, II, and III was 35.5 +/- 6.3, 109.6 +/- 10.6, and 196.2 +/- 34.9 ng/min/g respectively, values which also were significantly different among groups (P < 0.001)" 10/01/1999 - "Linoleic acid, via its mitogenic metabolite 13-hydroxyoctadecadienoic acid (13-HODE) is an important growth stimulant of rat hepatoma 7288CTC" 09/15/1999 - "13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo." Order ALL the reference details at left...
4.	Breast Neoplasms (Breast Cancer) 09/01/2005 - "Here we tested the hypothesis that plasma eicosapentaenoic acid (EPA), an (n-3) fatty acid, suppresses cell proliferation in MCF-7 human breast cancer xenografts via a pertussis toxin-sensitive reduction of intratumor cAMP, LA uptake, and formation of the mitogen 13-hydroxyoctadecadienoic acid (13-HODE) from LA" 12/01/2005 - "Exposure of rats bearing rat hepatomas or human breast cancer xenografts to increasing intensities of white fluorescent light during each 12-hour dark phase (0-345 microW/cm2) resulted in a dose-dependent suppression of nocturnal melatonin blood levels and a stimulation of tumor growth and linoleic acid uptake/metabolism to the mitogenic molecule 13-hydroxyoctadecadienoic acid" 07/01/2005 - "Melatonin suppresses cAMP formation and inhibits tumor uptake of LA and its metabolism to 13-HODE via a melatonin receptor-mediated mechanism in both tissue-isolated rat hepatoma 7288 CTC and human breast cancer xenografts" Order ALL the reference details at left...
5.	Wounds and Injuries (Trauma) 08/01/2003 - "These results suggest that wound-responsive JA burst may trigger the early phase of LOX expression which facilitates biosynthesis of endogenous JA through its 13-LOX activity, and subsequently leads to the activation of the late phase LOX expression in MeJA-treated maize seedlings" 07/01/2002 - "The results suggest that the wound response in passion fruit plants may be mediated by a chloroplast 13-LOX, a key enzyme of the octadecanoid defense-signaling pathway." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Melatonin
2.	13-hydroxy-9,11-octadecadienoic acid
3.	15-hydroxy-5,8,11,13-eicosatetraenoic acid
4.	Linoleic Acid (Linoleate)
5.	Lipoxygenase (Lipoxygenase-1)
6.	Thymidine
7.	DNA (Deoxyribonucleic Acid)
8.	Melatonin Receptors (Melatonin Receptor)
9.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
10.	Leukotriene B4

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18521 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>